Medical management of severe gastrointestinal bleeding can present a therapeutic challenge. We describe a case of bleeding secondary to gastric cancer that failed to settle, despite treatment with tranexamic acid, etamsylate and sucralfate. Thalidomide was prescribed for its antiangiogenic properties. Bleeding settled within 1 week of starting 300 mg of thalidomide nocte. The effect appeared to be dose dependant, with bleeding recurring only when the dose was reduced to 100 mg of thalidomide nocte.
1 Eleutherakis-Papaiakovou V Bamias A Dimopoulos A . Thalidomide in cancer medicine. Ann Oncol2004; 15: 1151–1160.
2.
2 Peuckmann V Fisch M Bruera E . Potential novel uses of thalidomide. Focus on palliative care. Drugs2000; 60: 273–292.
3.
3 Deaner PB . The use of thalidomide in the management of severe sweating in patients with advanced malignancy: trial report. Palliat Med2000; 14: 429–431.
4.
4 Daly MB Shuster S . Antipruritic action of thalidomide. Acta Derm Venereol2000; 80: 24–25.
5.
5 Bauditz J Schanchschal G Wedel S Lochs H . Thalidomide for the treatment of severe intestinal bleeding. Gut2004; 53: 609–612.
6.
6 Karajeh MA Hurlstone DP Stephenson TJ Ray-Chaudhuri D Gleeson DC . Refractory bleeding from portal hypertensive gastropathy: a further novel role for thalidomide therapy? Eur J Gastroenterol Hepatol2006; 18: 545–548.
7.
7 Craanen ME van Triest B Verheijen RHM Mulder CJJ . Thalidomide in refractory haemorrhagic radiation induced proctitis. Gut2006; 55: 1371–1372.
